Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: A method of treating leukemia in a patient, the method including obtaining a plasma sample from a patient at a first time point and at a second time point, measuring a gene expression level of a set of core clock genes, and at least one of a first set of peripheral clock genes and a second set of peripheral clock genes, each in the plasma sample at the first time point and in the plasma sample at the second time point. Then determining that a first treatment is effective or ineffective for the patient when a correlation of the gene expression level of the set of core clock genes, the first set of peripheral clock genes, and the second set of peripheral clock genes, and treating the patient accordingly.

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Abstract: An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 ?l?1 of amniotic cells, the osmolarity of the composition being in the range from 240.0 mosm/l to less than 308.0 mosm/l, and the chloride ion concentration in the composition being not more than 130.0 mmol/l. An aqueous composition for application with an amniotic infusion, the composition containing less than 70 ?l?1 of amniotic cells and comprising at least one surfactant, is also disclosed.

Abstract: An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 ?l?1 of amniotic cells, the osmolarity of the composition being in the range from 240.0 mosm/l to less than 308.0 mosm/l, and the chloride ion concentration in the composition being not more than 130.0 mmol/l. An aqueous composition for application with an amniotic infusion, the composition containing less than 70 ?l?1 of amniotic cells and comprising at least one surfactant, is also disclosed.

Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.

Abstract: The invention relates to an aqueous ionic solution, particularly for nasal use, including: at least one seawater solution having an osmolality of between 290 mOsm/kg and 400 mOsm/kg in a weight proportion of between about 30 and 98 wt % relative to the total weight of the composition; at least one cationic phospholipid of natural origin in a weight proportion of between about 0.01 and 5 wt % relative to the total weight of the composition; and at least one compound, which is originally immiscible with said seawater solution, in a weight proportion of between 0.01 and 10 wt % relative to the total weight of the composition.

Abstract: This invention provides concentrated aqueous biocidal solutions formed from bromine chloride, sodium hydroxide, and sulfamic acid. The weight ratio of bromine chloride:sodium hydroxide:sulfamic acid used in forming the concentrated solution is such that for every 10.5 to 11.5 parts by weight of bromine chloride used, 15.3 to 17.5 parts by weight of sodium hydroxide and 11.0 to 12.5 parts by weight of sulfamic acid are used, the biocidal solution containing at least about 100,000 ppm (wt/wt) of active bromine based on the total weight of the solution.

Abstract: The present invention relates to systems and methods for generating germicidal compositions for use in a wide variety of settings, including agricultural settings (e.g., animal bedding), food production settings, hospitality settings, health care settings, health club settings, exercise facility settings, research based settings, veterinarian settings, medical settings, hydraulic fracturing settings, and/or any setting requiring disinfection.

Abstract: The present invention provides a method for preparing a material in the form of liquid for forming an antimicrobial surface coating with multi-level antimicrobial properties, comprising: encapsulating one or more volatile or gaseous biocides in two or more amphiphilic block copolymers to obtain a w/o/w double emulsion, and mixing the w/o/w double emulsion with one or more nonvolatile biocides, each of which is selected from the group consisting of a metal containing biocide, triclosan, a carboxylic acid, a sugar acid and a combination thereof.

Abstract: The present invention is directed to a method, system and equipment for the elaboration of electrolytic chlorine oxidants, hypochlorous acid and sodium hypochlorite substances, using elements that result in an ecological process and confers a high efficiency in the production of these substances, permitting the generation of a product of very high performance and efficiency.

Abstract: A gel, in particular for use in a wound treatment agent includes an inorganic silicate as thickener; and an electrochemically activated aqueous common salt solution having a content of free chlorine of more than 200 mg/l and a conductivity of not more than 12 mS/cm.

Abstract: An aqueous biocidal composition comprising a mixture of hydrochloric acid (HCl), urea, and sodium hypochlorite (NaOCl) at acidic pH, a method for manufacturing the composition and a biocidal technology for treating industrial water.

Abstract: Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions.

Abstract: A skin external composition comprising a combination of salt and sugar as an active ingredient in an amount effective to treat and prevent vaginosis, together with a pharmaceutically acceptable carrier, and the use thereof.

Abstract: A bone graft substitute in the form of an implantable three-dimensional scaffold that includes calcium phosphate and has pores. The scaffold is impregnated with a calcium and/or phosphate containing substance, and the dissolution rate DRS of the scaffold is slower than the dissolution rate DRD of the calcium and/or phosphate containing substance.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: The described pKa process creates a unique combination of active ingredients. The calcium carbonate carrier is impregnated with various proportions of active ingredients and the compounds are made more effective by the sheer and absorption action as they are combined in the described process. The calcium carrier is adjusted to incorporate small amounts of highly efficient/effective pH adjusters. No natural solution exists in Nature with a pH of 10.6 that is optimal for adjusting the pKa naturally in foods. The present invention effects a change in the pKa of most acids and therefore impacts pH which can positively affect flavor, color and taste. The reduced moisture process in combination with the invention solution applied as a treatment results in fruits and vegetables that exhibit cleaner flavors, better texture, enhanced color and lower microbial counts than is found in standard IQF vegetables currently available.

Abstract: The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material.

Abstract: The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.

Abstract: Disclosed are oral rehydration compositions with sucrose, or alternatively fructose and glucose in a 1:1 ratio. The compostion further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same.

Abstract: Described are highly concentrated liquid biocidal solutions formed in water from (a) specified bromine sources (e.g., BrCl or mixtures of BrCl and Br2) and (b) alkali metal salt of sulfamic acid and/or sulfamic acid and alkali metal base, wherein the solution contains >160,000 ppm of active bromine. Solutions of this type have been found to have greater stability than a commercially-available solution made from the same components containing 148,600 ppm of active bromine. Also described are new, water-soluble, solid state biocidal products formed by removing the water from solutions made in water from (a) and (b) irrespective of the initial concentration of active bromine. Removal of water can be accomplished by flashing or distillation at reduced pressure or preferably by spray drying. Such solid state products are typically in the form of powders or small particles, but can be compacted into larger forms preferably with the aid of one or more suitable binding agents.

Abstract: The invention relates to the use, in a cosmetic or dermatological composition, of a particular water having a pH of between 7.8 and 10 and a total dissolved solids (TDS) concentration of between 10 and 250 mg/l. The invention also relates to a cosmetic or dermatological composition containing this water. The invention relates in particular to a treatment method intended for preventing or delaying the appearance of the effects of intrinsic and/or extrinsic ageing of the skin, or for slowing down the effects thereof; for preventing or reducing pigmentary spots on the skin, or the coloration of hyperpigmented areas of skin; for reducing the pigmentation of the periphery of depigmented areas; for improving the uniformity of the skin coloration; or for lightening the complexion of the skin.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: The invention includes convenient methods of preparing: (1) highly concentrated liquid bromine-containing biocidal solutions, (2) highly concentrated mixed halogen liquid bromine and chlorine-containing biocidal solutions, and (3) high-activity bromine-containing biocidal solids, all having excellent physical and chemical stability. One method yields solutions that have concentrations of bromine in excess of 18% as Br2 (8% as Cl2) in which the mole ratio of hydroxide ion to hydrogen ion source is at least 1.9:1. Another method employs elemental bromine in conjunction with a solid organic or inorganic halogenating agent to yield halogen solutions at concentrations greater than 22.9% as Br2 (10.2% as Cl2). This method can be performed under conditions that exceed the solubility of the active ingredient such that it crystallizes and is recovered as a hydrated or anhydrous salt in good yield.

Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.

Abstract: Normal saline and other infusate solutions for infusion into the body of a patient during medical treatment are disclosed. In particular, infusates are disclosed that are formulated to resist changes to the pH of the solution when subjected to sterilization procedures that employ ethylene oxide gas. In one embodiment, a buffered infusate suitable for disposal in a syringe or other container is disclosed. The syringe is sterilizable using ethylene oxide. The buffered infusate comprises an aqueous solution that is disposed in the syringe and is suitable for infusion into a body of a patient. A buffer component is added to the aqueous solution to form a buffered solution. The buffer component is configured to resist a change in the pH of the buffered solution upon exposure of the buffered solution to the ethylene oxide during sterilization of the syringe.

Abstract: Disclosed are oral rehydration compositions with sucrose, sodium, chloride, and citric acid or citrate. The composition further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: The present invention relates to a pharmaceutical combination for the treatment of renal failure in pets, caused by various diseases or ineffective to traditional renal therapy or renal replacement therapy thereby incapable of restoring health. The pharmaceutical combination of the present invention is administered by subcutaneous injection to pets in need thereof, with various advantages including simple use, no requirement for surgery, hospitalization and/or fluid infusion, faster recovery of health status, reduced medical costs, significantly improved recovery rate, reduced mortality and the likes. The pharmaceutical combination of the present invention can also be used for the continuous care treatment of pets with renal failure.

Abstract: The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to 2.7% w/v sodium chloride/water with the most preferred concentration being 2.4% to 2.6% w/v of sodium chloride in water brings maximum relief of congestion without causing irritation or discomfort.

Abstract: The present invention relates to an oil-in-water emulsion comprising at least one mucomimetic polymer, at least one lipid of phospholipid type, at least one lipid other than the phospholipid, at least one stabilizing polymer, and a hydrophilic liquid, to an emulsion comprising an aqueous phase that contains at least one stabilizing polymer and at least one mucomimetic polymer, and an oily phase that contains at least one lipid of phospholipid type and a lipid other than the phospholipid, to a medicament comprising one of these emulsions, and to the use of one of these emulsions as an agent for restoring and/or replacing the lachrimal film or as a carrier for an active compound.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: Described are highly concentrated liquid biocidal solutions formed in water from (a) specified bromine sources (e.g., BrCl or mixtures of BrCl and Br2) and (b) alkali metal salt of sulfamic acid and/or sulfamic acid and alkali metal base, wherein the solution contains >160,000 ppm of active bromine. Solutions of this type have been found to have greater stability than a commercially-available solution made from the same components containing 148,600 ppm of active bromine. Also described are new, water-soluble, solid state biocidal products formed by removing the water from solutions made in water from (a) and (b) irrespective of the initial concentration of active bromine. Removal of water can be accomplished by flashing or distillation at reduced pressure or preferably by spray drying. Such solid state products are typically in the form of powders or small particles, but can be compacted into larger forms preferably with the aid of one or more suitable binding agents.

Abstract: A low pH wipe is produced having no other buffering or modifying agents, using water only. The water has been modified by means of a reactor to produce an excess of hydronium ions to lower the pH.

Abstract: A bone graft substitute in the form of an implantable three-dimensional scaffold that includes calcium phosphate and has pores. The scaffold is impregnated with a calcium and/or phosphate containing substance, and the dissolution rate DRS of the scaffold is slower than the dissolution rate DRD of the calcium and/or phosphate containing substance.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.

Abstract: Provided is a method for treating or preventing peritonitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. Further provided is a method for preventing peritoneal hemorrhage, adhesions and abscesses.

Abstract: The present invention provides methods of treating, reducing, and/or preventing the incidence of an influenza related viral infection in a patient comprising administering a therapeutically effective amount of an oxidative reductive potential (ORP) water solution. The present invention also provides methods of reducing or preventing the incidence of an influenza related viral infection in a patient associated with a medical device comprising contacting the medical device with an effective amount of an ORP water solution.

Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.

Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: Corrosion inhibitor compositions and methods of use are disclosed. Sugar acids and calcium corrosion inhibitors combined with hypochlorite sources provide use solutions for effective corrosion inhibition for metal surfaces.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: Methods for processing substrate surfaces carrying coatings comprising a metal are disclosed. The methods involve providing a substrate surface having a coating comprising a metal, and exposing the substrate surface to a mixture including an oxidizing agent and an anion.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: Methods for inhibiting sensory responses in the skin such as pain and itch using topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle are disclosed.

Abstract: The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.

Abstract: The present invention describes a method and compositions by which introducing PO4?3 ion at particular stage in the preparation of aluminum/zirconium solutions surprisingly results in significantly improved zirconium molecular weight stability.